Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)

References

• International Diabetes FederationIDF Diabetes Atlas7th ed20151140 Available from: http://www.diabetesatlas.org/Accessed October 10, 2017
   Google Scholar
• SeshasaiSRKKaptogeSThompsonAEmerging Risk Factors CollaborationDiabetes mellitus, fasting glucose, and risk of cause-specific deathN Engl J Med2011364982984121366474
   PubMed Web of Science ®Google Scholar
• SchernthanerGJarvisSLotanCPráznýMWannerCWascherTCAdvances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 DiabetesTher Clin Risk Manag201713697928144148
   PubMed Web of Science ®Google Scholar
• ZinmanBInzucchiSELachinJMRationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Cardiovasc Diabetol201413110224943000
   PubMed Web of Science ®Google Scholar
• MarsoSPDanielsGHBrown-FrandsenKLiraglutide and cardiovascular outcomes in type 2 diabetesN Engl J Med2016375431132227295427
   PubMed Web of Science ®Google Scholar
• WannerCInzucchiSELachinJMEmpagliflozin and progression of kidney disease in type 2 diabetesN Engl J Med2016375432333427299675
   PubMed Web of Science ®Google Scholar
• MarsoSPBainSCConsoliASemaglutide and cardiovascular outcomes in patients with type 2 diabetesN Engl J Med2016375191834184427633186
   PubMed Web of Science ®Google Scholar
• NealBPerkovicVMahaffeyKWCanagliflozin and cardiovascular and renal events in type 2 diabetesN Engl J Med2017377764465728605608
   PubMed Web of Science ®Google Scholar
• PatelAMacMahonSChalmersJADVANCE Collaborative GroupIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med2008358242560257218539916
   PubMed Web of Science ®Google Scholar
• BergenstalRMBaileyCJKendallDMType 2 diabetes: assessing the relative risks and benefits of glucose-lowering medicationsAm J Med20101234374
   Web of Science ®Google Scholar
• UKPDS Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• HaywardRAReavenPDWiitalaWLFollow-up of glycemic control and cardiovascular outcomes in type 2 diabetesN Engl J Med2015372232197220626039600
   PubMed Web of Science ®Google Scholar
• Ismail-BeigiFGenuthSClinical implications of the ACCORD trialJ Clin Endocrinol Metab2012971414822049171
   PubMed Web of Science ®Google Scholar
• Ismail-BeigiFCravenTBanerjiMAEffect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trialLancet2010376973941943020594588
   PubMed Web of Science ®Google Scholar
• ZoungasSChalmersJNealBFollow-up of blood-pressure lowering and glucose control in type 2 diabetesN Engl J Med2014371151392140625234206
   PubMed Web of Science ®Google Scholar
• DalrympleLSKatzRKestenbaumBChronic kidney disease and the risk of end-stage renal disease versus deathJ Gen Intern Med201126437938520853156
   PubMed Web of Science ®Google Scholar
• RoncoCHaapioMHouseAAAnavekarNBellomoRCardiorenal syndromeJ Am Coll Cardiol200852191527153919007588
   PubMed Web of Science ®Google Scholar
• WakisakaMLetter to the editor on: Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetesN Engl J Med2016375181799180227806237
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• FitchettDZinmanBWannerCHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trialEur Heart J201637191526153426819227
   PubMed Web of Science ®Google Scholar
• Jardiance 10 mg and 25 mg film-coated tablets [prescribing information]. (eMC) Print friendly, 2017GermanyBoehringer Ingelheim Limited
   Google Scholar
• Jardiance [prescribing information]Ingelheim am RheinGermanyBoehringer Ingelheim International GmbH2016134
   Google Scholar
• LehmannRBiandaTBrändleMMesures Visant Contrôle De La Glycémie Chez Les Patients Atteints De Diabète Sucré De Type 2. [Recommendations of SGED/SSED: Measures for blood glucose control in patients with type 2 diabetes mellitus]2016117BadenSociété Suisse d’Endocrinologie et de Diabétologie French. Available from: http://sgedssed.ch/fr/informations-pour-professionnels/lignes-directrices/Accessed October 10, 2017
   Google Scholar
• LehmannRBiandaTBrändleMEmpfehlungen der SGED/SSED: Massnahmen zur Blutzuckerkontrolle bei Patienten mit Diabetes mellitus Typ 2. [Recommendations of SGED/SSED: Measures for blood glucose control in patients with type 2 diabetes mellitus]2016116BadenSchweizerische Gesellschaft für Endokrinologie und Diabetologie German. Available from: http://sgedssed.ch/informationen-fuer-fachpersonen/richtlinien-guidelines/Accessed October 10, 2017
   Google Scholar
• ŠkrhaJPelikánováTKvapilMČeská diabetologická společnostCzech Diabetes Society Recommended treatment for type 2 diabetes mellitusPrague2016115 Czech
   Google Scholar
• Austrian Diabetes Society (ODG) and the Austrian Lipid ConsensusCo-ordinated by Clodi M. and Toplak H. Diabetes mellitus – Instructions for practice. Revised and extended version 2016. Wiener klinische wochenschriftThe Central European Journal of Medicine2016128S37S228 German
   Google Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert CommitteePharmacologic management of type 2 diabetes: 2016 interim updateCan J Diabetes201640648448627912867
   PubMed Web of Science ®Google Scholar
• DedovIIShestakovaMVMayorovAYStandards of specialized diabetes careDiabetes Mellitus2017201S1121
   Google Scholar
• PiepoliMFHoesAWAgewallS2016 European guidelines on cardiovascular disease prevention in clinical practiceEur Heart J201637292315238127222591
   PubMed Web of Science ®Google Scholar
• PonikowskiPVoorsAAAnkerSD2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failureEur Heart J201637272129220027206819
   PubMed Web of Science ®Google Scholar
• RoffiMPatronoCColletJ-P2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)Eur Heart J201637326731526320110
   PubMed Web of Science ®Google Scholar
• FDAFDA drug safety communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density2015 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm461449.htmAccessed April 27, 2017
   Google Scholar
• PRAC, Committee PRAPRAC recommendation, EMA/76661/20172017 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors_Canagliflozin_20/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500221431.pdfAccessed April 27, 2017
   Google Scholar
• KohlerSPatelSDeFronzoRASafety and tolerability of combinations of empagliflozin/linagliptin for 52 weeks in subjects with type 2 diabetes2015 Available from: http://www.easdvirtualmeeting.org/resources/safety-and-tolerability-of-combinations-of-empagliflozin-linagliptin-for-52-weeks-in-subjects-with-type-2-diabetes--3Accessed October 10, 2017
   Google Scholar
• Standards of medical care in diabetes-2017: summary of revisionsDiabetes Care201740Suppl 1S4S527979887
   PubMedGoogle Scholar
• GreenJBBethelMAArmstrongPWEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med2015373323224226052984
   PubMed Web of Science ®Google Scholar
• PfefferMAClaggettBDiazRLixisenatide in patients with type 2 diabetes and acute coronary syndromeN Engl J Med2015373232247225726630143
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
   PubMed Web of Science ®Google Scholar
• WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327133523992602
   PubMed Web of Science ®Google Scholar
• SonessonCJohanssonPAJohnssonEGause-NilssonICardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysisCardiovasc Diabetol2016153726895767
   PubMed Web of Science ®Google Scholar
• KosiborodMCavenderMAFuAZLower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL studyCirculation Epub2017518
   Web of Science ®Google Scholar
• NyströmTBodegårdJNathansonDThuressonMNorhammarAErikssonJWNovel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetesDiabetes Obes Metab20173561364
   Google Scholar
• ToulisKAWillisBHMarshallTAll-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvement network databaseJ Clin Endocrinol Metab201710251719172528323967
   PubMed Web of Science ®Google Scholar
• BirkelandKIJorgensenMECarstensenBCardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysisLancet Diabetes Endocrinol20175970971728781064
   PubMed Web of Science ®Google Scholar
• ShahADLangenbergCRapsomanikiEType 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million peopleLancet Diabetes Endocrinol20153210511325466521
   PubMed Web of Science ®Google Scholar
• ScheenAJDiabetes: time for reconciliation between cardiologists and diabetologistsNat Rev Cardiol201613950951027411401
   PubMed Web of Science ®Google Scholar